ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

Chi Van Dang Named Director of University Of Pennsylvania Abramson Cancer Center

July 15, 2011

Varmus: NCI Needs To Rethink, Review; Programs Must Be “At A High Level”

November 12, 2010

Women’s Health: Treatment to Move Toward Pre-Cancer, Klausner Says

December 5, 1997

In Brief: AACR, ASCO to Sponsor Joint Symposium on Oncogenes; AACI Hosts Congressional Staff

February 15, 1985

Varmus: NCI Faces “Budgetary Disaster;” Flat Funds, Cuts Loom For Most Programs

January 14, 2011

To Become Effective Lobbyists, Scientists Seek Alliances With Patient Advocates

March 31, 1995